Track Apellis Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Apellis Pharmaceuticals, Inc. APLS Open Apellis Pharmaceuticals, Inc. in new tab

41.03 USD
P/E
38.35
EPS
1.07
P/B
12.65
ROE
46.02
Beta
-0.25
Target Price
40.92 USD
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc.

🧾 Earnings Recap – Q3 2025

Apellis Pharmaceuticals delivered a strong third quarter in 2025, highlighted by the FDA approval of EMPAVELI for C3 glomerulopathy, enhancing its market position with differentiated treatment options.

  • EMPAVELI's approval increases the addressable market by approximately 5,000 patients, positioning it as the only comprehensive treatment for multiple patient populations.
  • Early feedback on EMPAVELI's launch has been overwhelmingly positive, with physicians emphasizing its efficacy and ease of use via a compact auto-injector.
  • SYFOVRE continues to face slow adoption despite its proven clinical profile, prompting strategic marketing initiatives aimed at accelerating growth in the geographic atrophy market.
📅
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateJuly 30, 2026
P/E38.35
EPS1.07
Book Value3.24
Price to Book12.65
Debt/Equity114.66
% Insiders11.365%
Growth
Revenue Growth0.61%
Estimates
Forward P/E-103.09
Forward EPS-0.40
Target Mean Price40.92

DCF Valuation

Tweak assumptions to recompute fair value for Apellis Pharmaceuticals, Inc. (APLS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Apellis Pharmaceuticals, Inc. Logo Apellis Pharmaceuticals, Inc. Analysis (APLS)

United States Health Care Official Website Stock

Is Apellis Pharmaceuticals, Inc. a good investment? Apellis Pharmaceuticals, Inc. (APLS) is currently trading at 41.03 USD. Market analysts have a consensus price target of 40.92 USD. This suggests the asset is currently trading above analyst expectations.

In terms of valuation, the stock trades at a P/E ratio of 38.35. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Apellis Pharmaceuticals, Inc. is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is -0.40.

Investor FAQ

Does Apellis Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Apellis Pharmaceuticals, Inc.?

Apellis Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of 1.07.

Company Profile

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. As of May 14, 2026, Apellis Pharmaceuticals, Inc. operates as a subsidiary of Biogen Inc.

Exchange Ticker
NMS (United States) APLS
FRA (Germany) 1JK.F

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion